Actualización normativa

Cardiovascular disease is the leading cause of death in Fabry disease patients.¹ Undiagnosed and untreated Fabry disease leads to progressive, irreversible, life-threatening heart injury.^2,3

Cardiovascular disease is the leading cause of death in Fabry disease patients.¹ Undiagnosed and untreated Fabry disease leads to progressive, irreversible, life-threatening heart injury.^2,3

Cardiovascular disease is the leading cause of death in Fabry disease patients.¹ Undiagnosed and untreated Fabry disease leads to progressive, irreversible, life-threatening heart injury.^2,3

Learn more about what and why.

Think Fabry, think renal involvement that may present early in life and could go undetected.

Think Fabry, think renal involvement that may present early in life and could go undetected.

Think Fabry, think renal involvement that may present early in life and could go undetected.

Think Fabry, think renal involvement that may present early in life and could go undetected.

The Soli-Switch Study evaluates the real-world effectiveness and safety of switching adults with type 2 diabetes from basal insulin or GLP-1 RA therapy to iGlarLixi (insulin glargine 100 U/mL plus lixisenatide). The study explores glycaemic control, treatment adherence, and patient outcomes in clinical practice settings.

Think Fabry, think renal involvement that may present early in life and could go undetected.

Think Fabry, think screening at-risk family members.¹

Think Fabry, think screening at-risk family members.¹